P53-Based Strategy for Protection of Bone Marrow From Y-90 Ibritumomab Tiuxetan.

ABSTRACT:

Purpose

The main drawbacks of radioimmunotherapy have been severe hematological toxicity and potential development of myelodysplastic syndrome and secondary leukemia. Activation of p53 follows a major pathway by which normal tissues respond to DNA-damaging agents, such as chemotherapy and radiation therapy, that result in injuries and pathological consequences. This pathway is separate from the tumor suppressor pathway of p53. We have previously reported that use of low-dose arsenic (LDA) temporarily and reversibly suppresses p53 activation, thereby ameliorating normal tissue toxicity from exposure to 5-fluorouracil and X rays. We have also demonstrated that LDA-mediated protection requires functional p53 and thus is selective to normal tissues, as essentially every cancer cell has

SUBMITTER: Su H 

PROVIDER: S-EPMC4509863 | biostudies-literature | 2015 Aug

REPOSITORIES: biostudies-literature